NSE: undefined BSE: undefined
₹-
(-%)
Mon, 23 Mar 2026, 09:46 am
Analysis
dividend
- Unable to evaluate Dr Lalchandani Labs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Dr Lalchandani Labs's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Dr Lalchandani Labs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Dr Lalchandani Labs is profitable, therefore cash runway is not a concern.
- Dr Lalchandani Labs is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 3.9x debt.
- Dr Lalchandani Labs's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (475.7% vs 22.2% today).
- Interest payments on debt are well covered by earnings (EBIT is 9.3x coverage).
- Dr Lalchandani Labs's level of debt (22.2%) compared to net worth is satisfactory (less than 40%).
- Operating cash flow is negative therefore debt is not well covered.
- High level of physical assets or inventory.
management
- Mohit's remuneration is lower than average for companies of similar size in India.
- Mohit's compensation has increased in line with Dr Lalchandani Labs recently becoming profitable.
- The average tenure for the Dr Lalchandani Labs board of directors is less than 3 years, this suggests a new board.
- The average tenure for the Dr Lalchandani Labs management team is less than 2 years, this suggests a new team.
misc
- Dr Lalchandani Labs is not covered by any analysts.
- Dr Lalchandani Labs's last earnings update was 218 days ago.
past
- Dr Lalchandani Labs has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
- Dr Lalchandani Labs's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
- Dr Lalchandani Labs used its assets less efficiently than the IN Healthcare industry average last year based on Return on Assets.
- Dr Lalchandani Labs's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Dr Lalchandani Labs has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Dr Lalchandani Labs has become profitable in the last year making it difficult to compare the IN Healthcare industry average.
value
- Dr Lalchandani Labs is good value based on assets compared to the IN Healthcare industry average.
- Dr Lalchandani Labs is good value based on earnings compared to the IN Healthcare industry average.
- Dr Lalchandani Labs is good value based on earnings compared to the India market.
- BSE:541299 is up 7% outperforming the Healthcare industry which returned 5.4% over the past month.
- 541299 underperformed the Healthcare industry which returned 9.1% over the past year.
- 541299 underperformed the Market in India which returned -14.5% over the past year.
- BSE:541299 is up 7% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800